Ligand Pharmaceuticals (LGND) EBT Margin (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted EBT Margin of 46.9% for Q1 2026, down 149.29% sequentially from 95.16% in Q4 2025, and up 6379.0% YoY from 0.72% in Q1 2025.
Ligand Pharmaceuticals (LGND) EBT Margin (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported EBT Margin for 17 years, with the latest figure at 46.9% in Q1 2026.
- Quarterly EBT Margin rose 6379.0% year-over-year to 46.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 67.36% (up 15613.0% YoY) and the FY2025 annual result came in at 59.29%, up 5779.0% from the prior year.
- EBT Margin fell to 46.9% in Q1 2026 per LGND's latest filing, from 95.16% in the prior quarter.
- Over five years, EBT Margin peaked at 366.22% in Q1 2024 and troughed at 157.45% in Q2 2024.
- A 5-year average of 24.21% and a median of 17.28% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin soared 23994 bps in 2024, then sank 47691 bps in 2025.
- Over 5 years, EBT Margin stood at 47.91% in 2022, then grew by 27 bps to 60.84% in 2023, then tumbled by 250 bps to 91.56% in 2024, then surged by 204 bps to 95.16% in 2025, then tumbled by 149 bps to 46.9% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 46.9%, 95.16%, and 122.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 100.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100.96% |
| Mar 31, 2026 | -46.90% |
| Dec 31, 2025 | 95.16% |
| Sep 30, 2025 | 122.24% |
| Jun 30, 2025 | 23.56% |
| Mar 31, 2025 | -110.69% |
| Dec 31, 2024 | -91.56% |
| Sep 30, 2024 | -12.23% |
| Jun 30, 2024 | -157.45% |
| Mar 31, 2024 | 366.22% |
| Dec 31, 2023 | 60.84% |
| Sep 30, 2023 | -36.95% |
| Jun 30, 2023 | 12.03% |
| Mar 31, 2023 | 126.28% |
| Dec 31, 2022 | 47.91% |
| Sep 30, 2022 | 20.86% |
| Jun 30, 2022 | 17.28% |
| Mar 31, 2022 | -25.04% |
| Dec 31, 2021 | 31.70% |
| Sep 30, 2021 | 25.56% |